Safety, Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 Deficiency

NCT ID: NCT04138251

Last Updated: 2019-10-28

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 5 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-06-20
• Study Completion Date: 2020-06-30

Brief Summary

Treatment of neutropenia of G6PC3 and Glycogenosis type 1b patients with empagliflozin

Detailed Description

Ubiquitous glucose-6-phosphatase deficiency (G6PC3) and glucose-6-phosphate transporter deficiency (G6PT/SLC37A4) both cause neutropenia. Studies on a G6PC3 deficient mouse model by Dr Veiga-da-Cunha and Prof. Van Schaftingen and colleagues have shown that these two proteins collaborate to hydrolyze a metabolite that exerts toxic effects on neutrophils. This metabolite is 1,5-anhydroglucitol-6-phosphate. It is formed by phosphorylation of a glucose analogue, 1,5-anhydroglucitol, which is present in the blood of all humans, mice and other mammals.

This discovery of the function of G6PC3 and G6PT opens up therapeutic prospects, in that lowering the concentration of 1,5-anhydroglucitol in the blood should reduce the concentration of 1,5-anhydroglucitol-6-phosphate in the cells and thus reduce its toxic effects. Veiga-da-Cunha, Van Schaftingen and colleagues have already shown that this is the case for a model of mice deficient in G6PC3 treated with empagliflozin .

Following these discoveries, the aim of the investigator's experiment is to test the effect of the efficacy of empagliflozin on urinary excretion and elimination of blood 1,5-anhydroglucitol in patients with glucose-6-phosphate transporter deficiency (type Ib glycogenosis) and patients with G6PC3 deficiency. This should allow patients to significantly lower the level of 1,5-anhydroglucitol-6-phosphate found in their neutrophils and thus cure their neutropenia.

Empagliflozin (marketed in Belgium under the name of Jardiance®) belongs to the class of drugs called oral hypoglycemic agents. It works on the kidney by inhibiting the glucose transporter in the proximal tubules, SGLT2, which leads to glucosuria that results in the elimination of 1,5-anhydroglucitol in the urine. At present, Empagliflozin alone or in combination with other drugs is commonly used in people with type 2 diabetes to control their blood sugar levels.

Conditions

Glycogen Storage Disease Type I; Glucose 6 Phosphatase Deficiency

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treatment

Oral empaglifozin 5 mg 1x/day, increase up to 10 mg 1x/day if no 25% decrease of blood1,5-anhydroglucitol level

Group Type: EXPERIMENTAL

Empagliflozin

Intervention Type: DRUG

oral administration of Empagliflozin

Interventions

Empagliflozin

oral administration of Empagliflozin

Intervention Type: DRUG

Other Intervention Names

Jardiance

Eligibility Criteria

Inclusion Criteria

• Glycogenosis type 1b confirmed by biochemical analyzes and / or genetic analysis. These patients with Glycogenosis must have had a liver transplant
• Alternatively, G6PC3 deficiency confirmed by genetic analysis
• Age 1 to 18 years old female or male
• Informed consent signed by the recipient and / or parents / assigns.
• Information and agreement of the referring medical team.
• A Negative Blood Pregnancy Test at the time of screening and a negative urinary pregnancy test at Day 1 of the protocol are required for female with child bearing potential.
• Sexually active patients should use an effective method of contraception throughout the duration of the study and up to 7 days after the last dose of Empaglifozine. (The combination of a hormonal method and a barrier method; Two barrier methods, the male condom being one of these two methods;Use intrauterine device or tubal ligation;-A total sex abstinence.)

Exclusion Criteria

• Presence of advanced fibrosis (Metavir F4) or cirrhosis.
• Impossibility of long-term and / or non-compliance monitoring.
• Other medical problems which, in the opinion of the physicians in charge of the patient, would constitute a contraindication to the procedure.
• Sexually active patients who do not consent to use effective contraception during the study.

• Minimum Eligible Age: 1 Year
• Maximum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Xavier Stephenne, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Cliniques universitaires St Luc

Locations

Cliniques universitaires Saint-Luc

Brussels, , Belgium

Site Status: RECRUITING

Countries

Belgium

Central Contacts

Xavier Stephenne, MD, PhD

Role: CONTACT

xavier.stephenne@uclouvain.be

32 2 7641377

Julia Versavau

Role: CONTACT

32 2 7641933

Facility Contacts

Xavier Stephenne, MD, PhD

Role: primary

xavier.stephenne@uclouvain.be

32 2 7641377

Related Links

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347702/

Proc Natl Acad Sci U S A. 2019 Jan 22;116(4):1241-1250. doi: 10.1073/pnas.1816143116. Epub 2019 Jan 9.

Other Identifiers

2018/26DEC/492

Identifier Type: -

Identifier Source: org_study_id